B-intervention	0	1	1
I-intervention	1	2	-
I-intervention	2	16	hexylcarbamoyl
I-intervention	16	17	-
I-intervention	17	18	5
I-intervention	18	19	-
I-intervention	19	31	fluorouracil
I-intervention	32	33	+
I-intervention	34	50	cyclophosphamide
I-intervention	51	52	+
I-intervention	53	62	tamoxifen
I-intervention	63	69	versus
I-intervention	70	73	CMF
I-intervention	74	75	+
I-intervention	76	85	tamoxifen
O	86	88	in
O	89	94	women
O	95	99	with
O	100	105	lymph
O	106	110	node
O	110	111	-
O	111	119	positive
O	120	126	breast
O	127	133	cancer
O	134	139	after
O	140	147	primary
O	148	155	surgery
O	155	156	:
O	157	158	a
O	159	169	randomized
O	170	180	controlled
O	181	186	trial
O	186	187	.

O	188	190	We
O	191	198	studied
O	199	202	the
O	203	213	usefulness
O	214	216	of
O	217	220	the
O	221	225	oral
O	226	227	5
O	227	228	-
O	228	230	FU
O	231	235	anti
O	235	236	-
O	236	242	cancer
O	243	247	drug
O	248	249	1
O	249	250	-
O	250	264	hexylcarbamoyl
O	264	265	-
O	265	266	5
O	266	267	-
O	267	279	fluorouracil
O	280	281	(
O	281	285	HCFU
O	285	286	)
O	287	288	+
O	289	305	cyclophosphamide
O	306	307	(
O	307	310	CPM
O	310	311	)
O	312	313	+
O	314	323	tamoxifen
O	324	325	(
O	325	328	TAM
O	328	329	)
O	330	331	(
O	331	334	HCT
O	335	340	group
O	340	341	)
O	342	344	in
O	345	355	comparison
O	356	360	with
B-control	361	364	CMF
I-control	365	366	+
I-control	367	370	TAM
O	371	372	(
O	372	376	CMFT
O	377	382	group
O	382	383	)
O	384	386	in
O	387	395	adjuvant
O	396	403	therapy
O	404	407	for
O	408	414	breast
O	415	421	cancer
O	422	424	by
O	425	426	a
O	427	430	non
O	430	431	-
O	431	442	inferiority
O	443	448	study
O	449	454	based
O	455	457	on
O	458	459	a
O	460	465	multi
O	465	466	-
O	466	479	institutional
O	480	485	joint
O	486	491	study
O	491	492	.

B-eligibility	493	501	Clinical
I-eligibility	502	507	stage
I-eligibility	508	509	I
I-eligibility	509	510	,
I-eligibility	511	513	II
I-eligibility	514	521	primary
I-eligibility	522	528	breast
I-eligibility	529	536	cancers
I-eligibility	537	541	with
I-eligibility	542	556	histologically
I-eligibility	557	565	positive
I-eligibility	566	574	axillary
I-eligibility	575	580	lymph
I-eligibility	581	585	node
I-eligibility	586	596	metastasis
O	597	601	were
O	602	610	randomly
O	611	619	assigned
O	620	622	to
O	623	626	the
O	627	630	HCT
O	631	636	group
O	637	639	or
O	640	643	the
O	644	648	CMFT
O	649	654	group
O	655	660	after
O	661	668	primary
O	669	676	surgery
O	676	677	.

O	678	680	We
O	681	691	registered
B-total-participants	692	695	136
O	696	701	cases
O	702	703	(
O	703	706	HCT
O	707	712	group
B-intervention-participants	713	715	68
O	716	721	cases
O	721	722	,
O	723	727	CMFT
O	728	733	group
B-control-participants	734	736	68
O	737	742	cases
O	742	743	)
O	743	744	.

O	745	747	No
O	748	759	significant
O	760	770	difference
O	771	773	in
O	774	777	the
B-outcome	778	779	5
I-outcome	779	780	-
I-outcome	780	784	year
I-outcome	785	792	overall
I-outcome	793	801	survival
I-outcome	802	806	rate
I-outcome	807	808	(
I-outcome	808	810	OS
I-outcome	810	811	)
O	812	815	and
O	816	819	the
B-outcome	820	821	5
I-outcome	821	822	-
I-outcome	822	826	year
I-outcome	827	834	disease
I-outcome	834	835	-
I-outcome	835	839	free
I-outcome	840	848	survival
I-outcome	849	853	rate
I-outcome	854	855	(
I-outcome	855	858	DFS
I-outcome	858	859	)
O	860	863	was
O	864	869	found
O	870	877	between
O	878	881	the
O	882	885	two
O	886	892	groups
O	892	893	.

O	894	896	In
O	897	900	the
O	901	911	stratified
O	912	920	analysis
O	920	921	,
B-outcome	922	925	DFS
O	926	928	in
O	929	934	cases
O	935	937	in
O	938	943	which
O	944	947	the
O	948	954	number
O	955	957	of
O	958	968	metastatic
O	969	974	lymph
O	975	980	nodes
O	981	984	was
O	985	986	1
O	986	987	-
O	987	988	3
O	989	992	was
O	993	1006	significantly
O	1007	1013	better
O	1014	1016	in
O	1017	1020	the
O	1021	1024	HCT
O	1025	1030	group
O	1031	1032	(
O	1032	1035	HCT
O	1036	1041	group
B-iv-bin-percent	1042	1044	84
I-iv-bin-percent	1044	1045	.
I-iv-bin-percent	1045	1046	3
I-iv-bin-percent	1046	1047	%
O	1047	1048	,
O	1049	1053	CMFT
O	1054	1059	group
B-cv-bin-percent	1060	1062	69
I-cv-bin-percent	1062	1063	.
I-cv-bin-percent	1063	1064	4
I-cv-bin-percent	1064	1065	%
O	1065	1066	,
O	1067	1070	log
O	1070	1071	-
O	1071	1075	rank
O	1076	1080	test
O	1081	1082	p
O	1082	1083	=
O	1083	1084	0
O	1084	1085	.
O	1085	1089	0496
O	1089	1090	)
O	1090	1091	.

O	1092	1094	No
O	1095	1106	significant
O	1107	1117	difference
O	1118	1120	in
O	1121	1124	the
O	1125	1130	total
O	1131	1140	incidence
O	1141	1143	of
B-outcome	1144	1151	adverse
I-outcome	1152	1159	effects
O	1160	1163	was
O	1164	1169	found
O	1170	1177	between
O	1178	1181	the
O	1182	1185	two
O	1186	1192	groups
O	1192	1193	,
O	1194	1197	but
O	1198	1203	there
O	1204	1208	were
O	1209	1222	significantly
O	1223	1227	less
B-outcome	1228	1235	adverse
I-outcome	1236	1243	effects
O	1244	1246	of
O	1247	1252	grade
O	1253	1254	2
O	1255	1257	or
O	1258	1262	over
O	1263	1265	in
O	1266	1269	the
O	1270	1273	HCT
O	1274	1279	group
O	1280	1281	(
O	1281	1282	p
O	1282	1283	=
O	1283	1284	0
O	1284	1285	.
O	1285	1288	034
O	1288	1289	)
O	1289	1290	.

O	1291	1294	The
O	1295	1298	QOL
O	1299	1305	survey
O	1306	1308	at
O	1309	1310	3
O	1311	1317	months
O	1318	1323	after
O	1324	1331	surgery
O	1332	1338	showed
O	1339	1340	a
O	1341	1352	significant
O	1353	1360	decline
O	1361	1363	of
O	1364	1367	the
B-outcome	1368	1371	QOL
O	1372	1381	regarding
B-outcome	1382	1391	lassitude
O	1391	1392	,
B-outcome	1393	1399	degree
I-outcome	1400	1402	of
I-outcome	1403	1413	difficulty
I-outcome	1414	1416	in
I-outcome	1417	1422	daily
I-outcome	1423	1427	life
O	1427	1428	,
B-outcome	1429	1441	satisfaction
I-outcome	1442	1446	with
I-outcome	1447	1456	treatment
O	1457	1460	and
B-outcome	1461	1468	present
I-outcome	1469	1473	mood
O	1474	1476	in
O	1477	1480	the
O	1481	1485	CMFT
O	1486	1491	group
O	1491	1492	.

O	1493	1498	Study
O	1499	1506	results
O	1507	1514	suggest
O	1515	1519	that
O	1520	1521	2
O	1521	1522	-
O	1522	1526	year
O	1527	1530	HCT
O	1531	1538	therapy
O	1539	1548	including
O	1549	1552	the
O	1553	1557	oral
O	1558	1559	5
O	1559	1560	-
O	1560	1562	FU
O	1563	1567	anti
O	1567	1568	-
O	1568	1574	cancer
O	1575	1579	drug
O	1580	1584	HCFU
O	1585	1587	is
O	1588	1589	a
O	1590	1596	useful
O	1597	1605	adjuvant
O	1606	1613	therapy
O	1614	1619	which
O	1620	1623	can
O	1624	1631	replace
O	1632	1636	CMFT
O	1637	1644	therapy
O	1645	1647	in
O	1648	1653	early
O	1654	1660	breast
O	1661	1667	cancer
O	1668	1673	cases
O	1674	1678	with
O	1679	1680	3
O	1681	1683	or
O	1684	1689	lower
O	1690	1700	metastatic
O	1701	1706	lymph
O	1707	1712	nodes
O	1712	1713	.
